AQR Arbitrage’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

AQR Arbitrage’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-98,528	Closed	-$12.8K	–	489
2024 Q4	$12.8K	Sell	98,528 -1,472	-1%	-$185	﹤0.01%	421
2024 Q3	$10.4K	Hold	100,000	–	–	﹤0.01%	449
2024 Q2	$11.1K	Hold	100,000	–	–	﹤0.01%	467
2024 Q1	$15K	Hold	100,000	–	–	﹤0.01%	450
2023 Q4	$15K	Hold	100,000	–	–	﹤0.01%	480
2023 Q3	$28K	Hold	100,000	–	–	﹤0.01%	498
2023 Q2	$23K	Hold	100,000	–	–	﹤0.01%	591
2023 Q1	$18K	Buy	+100,000	New	+$15.5K	﹤0.01%	759

AQR Arbitrage's BLACR Position: Q1 2025 in Review

AQR Arbitrage sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 98,528 shares — an estimated $12.8K sold.

AQR Arbitrage first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $28K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

AQR Arbitrage reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
AQR Arbitrage sold 98,528 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $12.8K.
AQR Arbitrage first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
AQR Arbitrage's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $28K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on AQR Arbitrage's 13F filing for Q1 2025, filed 15 May 2025.